Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 205-087-0 | CAS number: 133-06-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 17 October 1988 to 19 January 1989
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 989
- Report date:
- 1989
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.29 (Sub-Chronic Inhalation Toxicity:90-Day Study)
- Deviations:
- yes
- Remarks:
- Temperature and humidity levels were occasionally outside nominal range. One male and one female (both 12.98 μg/L) were returned to the wrong holding cage, resulting in pregnancy. The pregnant animal was subsequently terminated.
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 82-4 (90-Day Inhalation Toxicity)
- Deviations:
- yes
- Remarks:
- Temperature and humidity levels were occasionally outside nominal range. One male and one female (both 12.98 μg/L) were returned to the wrong holding cage, resulting in pregnancy. The pregnant animal was subsequently terminated.
- GLP compliance:
- yes
- Limit test:
- yes
Test material
- Reference substance name:
- Captan
- EC Number:
- 205-087-0
- EC Name:
- Captan
- Cas Number:
- 133-06-2
- Molecular formula:
- C9H8Cl3NO2S
- IUPAC Name:
- 2-[(trichloromethyl)sulfanyl]-2,3,3a,4,7,7a-hexahydro-1H-isoindole-1,3-dione
- Test material form:
- solid: particulate/powder
- Details on test material:
- - Name of test material: Captan, N-(trichloromethylthio)cyclohex-4-ene-1,2-dicarboximide
- Molecular formula: C9H8Cl3NO2S
- Molecular mass: 300.59
- Physical state: white powder
- Analytical purity: 88.7% (w/w)
- Batch number: 11240-37-1
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- - groups of 40 male and 40 female specific pathogen free, A1pk:APfSD (Wistar derived), albino rats
- Source: Barriered Animal Breeding Unit (BABU) Alderley Park. Cheshire. UK
- age: five to six weeks
- free access to mains drinking water and food, except during exposure periods when all food and water was removed.
- room temperature: 20-24°C
- relative humidity: 40-60%
Administration / exposure
- Route of administration:
- inhalation: dust
- Type of inhalation exposure:
- nose only
- Vehicle:
- air
- Details on inhalation exposure:
- Animals were exposed nose-only in restraining tubes supplied by Battelle, Geneva. Switzerland, which were Inserted into an ICl designed PERSPEX exposure chamber having an internal volume of approximately 46 litres. Animals were placed in the exposure chambers in replicate order with male and females on separate levels. Their exact position on each level was varied dally as was the level on which they were exposed. The exposure period commenced once the restraining tubes were inserted into the chambers and atmosphere generation had started. After six hours atmosphere generation was stopped and the animals were removed starting from the lowest group number. Temperature and relative humidity within each chamber during exposure were measured at approximately 30 minute intervals using a Vaisala HMI 31 portable digital temperature and humidity monitor (supplied by Vaisala UK Ltd. Cambridge, UK). Temperature and relative humidity were generally within the range of 22 ±3°C and 50 ±15% respectively. Some variation was seen in the latter, mainly during the earlier stages of the study and more frequently at the highest concentration but these are not considered to have affected the outcome of the study.Trial generations were carried out during a preliminary study. Atmospheres were generated into a reservoir chamber using a Wright's dust feed mechanism. A glass concentric jet atomiser was used above each exposure to create a venturi, which pulled test atmosphere from the reservoir chamber into the exposure chamber. Clean, dry air (dried and filtered using equipment supplied by Atlas-Copco, Sweden) was supplied to the exposure chamber via the atomiser and also directly, as diluting air. Airflow rates were measured using variable area flowmeters (KDG Flowmeters, Burgess Hill, Sussex, UK}. The airflow rates supplied to the atomisers were nominally: Group 2: 4.3 L/min (range 2.8-5.0 L/min), Group 3: 3.0 L/min (range 2.6-4.3 L/min), Group 4: 5.0 L/min (range 4.0-6.0 L/mln), Group 5: 16.0 L/mln (range 14.0-17.0 L/min}, Dilution air was supplied direct to the exposure chambers at the following flow rates (corrected to normal temperature and pressure): Group 1: 30 L/mln (range 29-30 L/mln), Group 2: 25 L/min (range 23-29 L/mln), Group 3: 25 L/mln (range 21-26 L/mln) Days 3 to 42: Group 4: 15 L/mln (range 15-15 L/min). Days 45 to 95: Group 4: 20 L/mln (range 19-25 L/mln). Days 3 to 42: Group 5: 0 L/mln. Days 45 to 95: Group 5: 8 L/mln (range 6-8 L/mln). At day 45 the volumes of diluting air supplied to the chambers of group 4 and 5 were altered. This was carried out in order to Increase the relative humidity of the air supplied to these chambers. This demonstrated that there were no significant differences in concentration between the top and bottom, and the front and back of the chamber.
- Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Atmospheres were sampled close to the animals breathing zone for determination of captan. The test atmosphere was drawn at a flow rate of 2 L/min over a measured time period, through a 25 mm diameter Vinyl Metrlcel (VN-I) filter housed in a Delrin open-faced filter holder (filters and holders supplied by Gelman Sciences Ltd., Northampton, UK).
The filter was weighed before and after sampling and the concentration was calculated.
All filters and the stages of the Cascade Impactor were store in sealed bottles after weighing prior to subsequent analysis of captan concentration. Test atmospheres were sampled at least 3 times during each exposure period. The amount of material collectes on the filters was insufficient to permit accurate weighing for the 0.1 and 0.5 µg/l captan groups. Therefore only the 5 and 15 µg/L captan concentrations were monitored gravimetrlcally during exposure using pre- and post sampling filter weights. For target concentrations of 0.1 and 0.5 µg/L capatn, a SIMSLIN (Safety in Mines Scattered Light Instrument), connected to a pen recorder was used as an aerosol monitor. This gives a continuous analogue recording which Is related to particulate concentration, thus permitt ng control of the concentration of the atmosphere during exposure. The SIMSLIN was alternated between the 0.1 and 0.5 µg/L captan exposure chambers throughout the exposure period. The 15 µg/L captan group was also monitored using SIMSLIN, starting in week 5. For the reasons given above concerning accuracy of gravimetric analysis of the atmospheres, only the analysed concentrations of captan are reported. The aerodynamJc particle size of the test atmospheres were measured each day during the first week and once a week thereafter by means of a Marple Cascade Impactor {supplied by Shaeffer Instruments Ltd, Wantage, Oxon, UK) which aerodynainically separates airborne particles into pre-determined size ranges The mean amount of analysed captan, in each size range, was then used to calculate the aerodynamic particle size distribution of the aerosol. Using a nicrocomputer the data was transformed using a log/probit transform and a linear regression derived from the cumulative data. Using this regression line, the mass median aerodynamic diameter {D50) and geometric standard deviation (GSD) were calculated. - Duration of treatment / exposure:
- 13-week inhalation
- Frequency of treatment:
- six hours per day, 5 days per week
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/L air (nominal)
- Remarks:
- Doses / Concentrations:0.1 μg/L captan (10/sex/dose)Basis:nominal conc.
- Dose / conc.:
- 0.001 mg/L air (nominal)
- Remarks:
- Doses / Concentrations:0.5 μg/L captan (10/sex/dose)Basis:nominal conc.
- Dose / conc.:
- 0.005 mg/L air (nominal)
- Remarks:
- Doses / Concentrations:5.0 μg/L captan (10/sex/dose)Basis:nominal conc.
- Dose / conc.:
- 0.015 mg/L air (nominal)
- Remarks:
- Doses / Concentrations:15 μg/L captan (20/sex/dose)Basis:nominal conc.
- No. of animals per sex per dose:
- 1. 0.1 μg/L captan (10/sex/dose)
2. 0.5 μg/L captan (10/sex/dose)
3. 5.0 μg/L captan (10/sex/dose)
4. 15 μg/L captan (20/sex/dose)5. control group of 20 males and 20 females was exposed to air only - Control animals:
- yes, concurrent vehicle
- Details on study design:
- In a 13-week inhalation (nose only) study with captan (purity 88.7%, batch number 11240-37-1), ALpk:APfSD (Wistar derived) rats were exposed to nominal concentrations of 0.1, 0.5 and 5.0 μg/L captan (10/sex/dose) and 15 μg/L captan (20/sex) for six hours per day, 5 days per week. Test atmospheres were generated by the suspension of captan particulate in air using a Wright dust feed generator. A concurrent control group of 20 males and 20 females was exposed to air only.
Examinations
- Observations and examinations performed and frequency:
- Parameters evaluated were mortality and clinical signs (daily and frequently during exposure body weight and food consumption (weekly), ophthalmoscopy (pretest, week 13 (0 and 15 μg/L) and week 18 (‘recovery’ group), haematology and clinical chemistry (study termination), urinalysis (males in week 13 and females in week 14), gross pathology, organ weights (lungs (with trachea attached but larynx removed), heart, liver, kidneys, brain, adrenal glands and testes) and histopathology. Kidney sections from control and high dose animals were taken for immunocytochemical detection of α-2u-globulin.
- Sacrifice and pathology:
- At the end of the exposure period 10 males and 10 females from each group were sacrificed from the main study group. The remaining animals (10/sex/dose - control and 15 μg/L) were sacrificed after a 4-week ‘recovery’ period and are referred to as the satellite group.
Results and discussion
Results of examinations
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Four males exposed to 12.98 μg/L captan were found dead over weeks 5 to 13 and another male from the same dose group was killed in extremis in week 11.
- Mortality:
- mortality observed, treatment-related
- Description (incidence):
- Four males exposed to 12.98 μg/L captan were found dead over weeks 5 to 13 and another male from the same dose group was killed in extremis in week 11.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- A statistically significant reduction in the body weight of males from all test groups compared to the control was noted during week 1. This divergence continued for the duration of the study for all test groups except 0.60 mg/L.
- Food consumption and compound intake (if feeding study):
- no effects observed
- Description (incidence and severity):
- Food intake in 5.06 and 12.98 μg/L males from the main group was reduced by approximately 10% versus controls, although these effects were not consistent and showed no dose relationship.
- Food efficiency:
- no effects observed
- Description (incidence and severity):
- Food efficiency was not affected by treatment.
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- no effects observed
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Blood: There were several statistically significant differences between control and test groups however, these were small and were not dose-related and were therefore considered not to be compound-related.
- Urinalysis findings:
- no effects observed
- Organ weight findings including organ / body weight ratios:
- no effects observed
- Gross pathological findings:
- effects observed, non-treatment-related
- Description (incidence and severity):
- Gross findings in the lungs of animals dead or sacrificed prior to study termination (red discolouration and partial deflation) were considered to be agonal and not treatment-related.
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Description (incidence and severity):
- Microscopic changes related to inhalation of captan were seen in the lung, larynx, nasal passages and trachea.
- Details on results:
- General observations: Four males exposed to 12.98 μg/L captan were found dead over weeks 5 to 13 and another male from the same dose group was killed in extremis in week 11. One 0.13 μg/L female and one 5.06 μg/L female were killed in extremis in week 6 and week 10, respectively, but were considered to be not treatment-related. Any observed clinical signs were associated with restraint and occurred equally in test animals and controls. Respiratory noise was present towards the end of the study, primarily in those animals in the higher dose groups. Mucus nasal secretion was noted in a few females and may have been related to treatment. Body weight gain in females was similar in all dose groups throughout the course of the study. A statistically significant reduction in the body weight of males from all test groups compared to the control was noted during week 1. This divergence continued for the duration of the study for all test groups except 0.60 mg/L, which returned to control levels from week 2 onward. By week 13 final body weights were statistically decreased by 8, 7 and 8% compared to the control in the 0.13, 5.06 and 12.98 μg/L dose groups, respectively. These were not considered to be a toxicologically significant effect. The body weights of males in the main study are summarised in Figure 5.3.3.1-1 (look at attached background material).
In the satellite study, body weight gain by 12.98 μg/L males was significantly lower than controls from week 1 through to the end of the recovery period at week 17. Final body weight was significantly lower than the control (Figure 5.3.3.1-1), (look at attached background material).
Food intake in 5.06 and 12.98 μg/L males from the main group was reduced by approximately 10% versus controls, although these effects were not consistent and showed no dose relationship. Food efficiency was not affected by treatment.
Ophthalmoscopy haematology and clinical chemistry: No treatment-related effects were observed.
Gross pathology, organ weights and histopathology: There were no macroscopic changesrelated to treatment with captan. Gross findings in the lungs of animals dead or sacrificed prior to study termination (red discolouration and partial deflation) were considered to be agonal and not treatment-related.
Microscopic changes related to inhalation of captan were seen in the lung, larynx, nasal passages and trachea. Treatment related (and agonal) effects for intercurrent and main group animals are summarised in Table 5.3.3.1-2 (look at attached background material) and Table 5.3.3.1-3 (look at attached background material).
Following a 4-week recovery period the lung and nasal passage effects had resolved, butthe larengyl effects (Table 5.3.3.1-4) (look at attached background material) were still present in the high dose group.There was no evidence of any treatment-related increase in α-2u-globulin in the kidney in either males or females from the 12.98 μg/L dose group. There were no treatment-related effects on absolute or relative organ weights. The factor contributing to death in intercurrent males exposed to 12.98 μg/L captan was considered to be necrosis of the bronchial/bronchiolar epithelium. This effect was also seen in 5.06 and 12.98 μg/L captan animals that survived to terminal sacrifice. Other treatmentrelated effects were consistent with repeated exposure to an irritant particulate and areconsidered to have no toxicological significance in the context of captan exposure to humans.
Effect levels
- Key result
- Dose descriptor:
- NOEC
- Effect level:
- 0.6 mg/m³ air (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: The NOEC for toxicological effects was 0.60 μg/L captan in both male and female rats, based on effects in the lung at doses of 5.06 μg/L and above.
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- The NOEC for toxicological effects was 0.60 μg/L captan in both male and female rats, based on effects in the lung at doses of 5.06 μg/L and above. It was not possible to establish an unequivocal NOEC.
- Executive summary:
Inhalation of captan may form a route of human exposure. The purpose of this study was to assess the sub-chronic inhalation toxicity of captan, following exposure to rats for 13 weeks (5 exposures/week) to determine effect and no-effect levels. Satellite groups were attached to the control and highest exposure groups and were retained after the last exposure for a 4-week observation period.
The rat was chosen since there is considerable general and toxicologlcal data available to assist in the interpretation of results. The Alpk:APfSD strain was used in the study since relevant background data were available. Groups of 10 male and 10 female AlpK:APfSD rats were exposed nose-only to target concentrations of 0.1, 0.5 or 5.0 µg/l captan, and 20 male and 20 female rats were exposed to 15.0 µg/l captan, for 6 hours per day, 5 days per week for 13 weeks. A concurrent control group of 20 male and 20 female rats was similarly treated but was exposed to air only. Ten males and 10 females from each group were killed in week 14 following their last exposure, and the remaining animals were killed in week 18 following a 4-week 'recovery' phase.
The mean atmospheric concentrations of captan throughout the study, analysed by gas chromatography were 0.13, 0.60, 5.06 and 12.98 µg/l. The test atmospheres had study mean mass median aerodynamic diameters of 0.95, 1.22, 1.57 and l.60 µm respectively for the 0.13, 0.60, 5.06 and 12.98 µg/l captan exposure levels and respective geometric standard deviations of 1.82, 1.80, 1.84 and 2.00.
No treatment-related changes were seen in ophthalmoscopy, clinical chemistry or haematological parameters in any exposed group. No evidence of kidney toxicity was seen in this study. Treatment-related effects were confined to the respiratory tract, were consistent with exposure to an irritant particulate and affects in the lung were considered responsible for five male mortalities during the study in the group exposed to 12.98 µg/l captan. Lungs from animals allowed to recover for 4weeks were completely normal. 0.60 µg/l captan is considered to be a no-effect level for the lung. The larynx was the only other organ to be affected. Effects considered to be of toxicological significance were seen at 12.98 and 5.06 µg/l. Effects considered to be an adaptive response to irritants were seen at the lower concentration. The toxicological no-effect level for inhalation (NOEL) for captan was considered to be 0.60 µg/l.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.